EFFICACY OF THE EXHALATION DELIVERY SYSTEM WITH FLUTICASONE IN PATIENTS WHO REMAIN SYMPTOMATIC ON STANDARD NASAL STEROID SPRAYS

Brent A. Senior, MD, Rodney J. Schlosser, MD, John Bosso, MD, and Zachary M. Soler, MD, MSc

 

 

Important Information

This study was funded by Optinose.

Optinose contributed to the study design, data interpretation, and writing of the report, as well as coordinating the data collection and analysis. The following authors have received compensation from Optinose: R.J. Schlosser, J. Bosso, and Z.M. Soler.

This publication contains information that is not consistent with the FDA-approved labeling for XHANCE. XHANCE is not indicated for the treatment of chronic rhinosinusitis without nasal polyps; the safety and efficacy of XHANCE for this use has not been established.

XHANCE is a corticosteriod indicated for the treatment of nasal polyps in patients 18 years of age and older.